https://register.epo.org/application?number=EP17783057
Lucid Diagnostics Announces Peer-Reviewed Publication Of Results From Three Clinical Utility Studies; Studies Demonstrate Real-World Clinical Utility Of EsoGuard Testing To Detect Esophageal Precancer
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ)))) ( "PAVmed"),
